Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CDC25A | P30304 | 3/20 | 0.42 |
| ▸ | CDC25B | P30305 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29906342 | 1.00 | TBXAS1 (0.50) | TBXAS1AURKAAURKBIDO1TDO2 | |
| SCHEMBL29906472 | 0.86 | PTPRC (0.49) | TBXAS1AURKAAURKBIDO1TDO2 | |
| SCHEMBL26982489 | 0.86 | PTPRC (0.49) | TBXAS1AURKAAURKBIDO1TDO2 | |
| SCHEMBL29906350 | 0.83 | TBXAS1 (0.53) | TBXAS1AURKAAURKBIDO1TDO2 | |
| SCHEMBL26982467 | 0.83 | TBXAS1 (0.53) | TBXAS1AURKAAURKBIDO1TDO2 | |
| SCHEMBL5810540 | 0.82 | TBXAS1 (0.62) | TBXAS1AURKAAURKBIDO1TDO2 | |
| SCHEMBL1506934 | 0.81 | CDC25A (0.45) | TBXAS1AURKAAURKBIDO1TDO2 | |
| SCHEMBL12833639 | 0.78 | TBXAS1 (0.59) | TBXAS1AURKAAURKBIDO1TDO2 | |
| SCHEMBL12833641 | 0.78 | CDC25A (0.51) | TBXAS1IDO1MAPTALDH1A1KDM4E | |
| SCHEMBL29906374 | 0.77 | TBXAS1 (0.45) | TBXAS1AURKAAURKBIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174589-A1 | PHOTOREDOX RADICAL BENZYLATION PROCESS | CENTRE NAT RECH SCIENT (FR) | 2024-05-30 | — | — | US | disclosed |
| EP-4301722-A1 | PHOTOREDOX RADICAL BENZYLATION PROCESS | Centre National de la Recherche Scientifique (FR) | 2024-01-10 | — | — | EP | disclosed |
| EP-4053096-A1 | PHOTOREDOX RADICAL BENZYLATION PROCESS | Centre national de la recherche scientifique (FR) | 2022-09-07 | — | — | EP | disclosed |
| US-9090549-B2 | 1,4-naphthoquinones derivatives and therapeutic use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-07-28 | — | — | US | disclosed |
| US-20110059972-A1 | 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059972-A1 | 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF | NQO1, NDUFV2, RECQL | TBXAS1 183/4885AURKA 1458/4885AURKB 740/4885 |
| US-20240174589-A1 | PHOTOREDOX RADICAL BENZYLATION PROCESS | H1-2, H1-3, H1-0 | TBXAS1 417/4885AURKA 4697/4885AURKB 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.